INMUNOTEK HELLAS is established in Athens, Greece, as a new European subsidiary of INMUNOTEK. With INMUNOTEK HELLAS, there are currently five subsidiaries of the INMUNOTEK Group around the world, and the second in Europe.
INMUNOTEK featured among the top-10 European immunotherapy providers by Pharma Tech Outlook, a specialized magazine in Pharma and Life Science technologies. The immunotherapy field covers different immune-based treatments for an increasing number of diseases. from allergies or cancer to autoimmune or infectious diseases.
INMUNOTEK is awarded for its research and innovative work in the field of Immunology in the IX Edition of the A TU SALUD Awards of the La Razón newspaper. The event was attended by the Mayor of Madrid, Mr. José Luis Martínez Almeida, who delivered the awards, and the Minister of Health of the Community of Madrid, Mr. Enrique Ruiz Escudero
The Spanish Ministry of Science and Innovation has granted the RETOS-Collaboration RTC2019-007097-1 project submitted by INMUNOTEK and the Complutense University of Madrid for the development of new vaccines for the treatment of food allergies. The approved project will experimentally address different vaccine prototypes against the main allergy-causing foods.
Their Majesties the Kings of Spain present INMUNOTEK with the National Innovation Award in the Small and Medium-Sized Entities (SME) category. The act presided over by the Kings took place at the Valencia Science Museum. It was attended by the Minister of Science and Innovation, Pedro Duque, local authorities. jury and guests. The National Innovation Award is the highest award given by the Government of Spain to recognize those entities that make innovation their main business growth strategy.
INMUNOTEK obtains the certificate as innovative entity in the private and independent blockchain network of the Spanish Science and Technology Parks (BLOCKPCT) promoted by the Association of Science and Technology Parks of Spain (APTE).
INMUNOTEK has implemented action measures to minimize the impact that the COVID-19 crisis is having due to the confinement situation established in Spain with the aim of guaranteeing the supply of its products to patients.
The MV130 project presented by INMUNOTEK has been selected by ITTN (International Technology Transfer Network) among more than 300 international projects for the first Roadshow sponsored by CAST (China Association for Science and Technology) in the fight against COVID-19. MV130 induces trained immunity and confers resistance to viral infections by activating innate immunity in a stable way through metabolic and epigenetic changes on innate immune cells.
The Chinese Patent Office has granted to INMUNOTEK the patent CN105492022B. This refers to hypoallergenic neoglycoconjugates performed with non-oxidized mannan derived from S. cerevisiae to be used for the development of novel allergy vaccines targeting dendritic cells.
Financial Times features INMUNOTEK as an example of a Spanish company with strong growth along the years even in unfavorable situations. According to the economic newspaper, the strength of these companies is based on their commitment to innovation and competitiveness. This allows to focus its productive activity towards foreign markets, have a sustained growth and create employment.